Compass Pathways (ADR)
Develops COMP360, an investigational psilocybin treatment with psychological support.
Something off on this page? Send us feedback.
Profile
Develops COMP360, a synthetic-psilocybin treatment paired with psychological support for treatment-resistant depression. Its clinical-stage model centers on regulatory development and potential commercialization, with no approved products.
COMP360 is a proprietary synthetic-psilocybin treatment administered with psychological support. Development has progressed from an international study in treatment-resistant depression to a Phase 3 program, while a Phase 2b/3 study addresses post-traumatic stress disorder. The program retains FDA Breakthrough Therapy and UK ILAP designations for treatment-resistant depression, but no indication has been approved.
Operations are based in London with a New York office, and work spans the United States, Europe, and the United Kingdom. Progress depends on completing clinical studies, regulatory approval, sufficient funding, trained healthcare professionals to monitor treatment, and eventual coverage and reimbursement.
Company facts
Categories
Key statistics
Year to date +109% · Average volume (30d) 2.7M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | Wells Fargo | Initiate | Positive | $13 | ||
| Jul 20, 2026 | B.Riley Financial | Target | $17 | |||
| Jul 8, 2026 | Evercore ISI | Upgrade | Outperform | |||
| Jul 8, 2026 | Evercore ISI Group | Upgrade | In Line | Outperform | ||
| Jul 7, 2026 | Stifel Nicolaus | Target | $21 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$0.46 | −$1.88 | −308.7% | — | — | — | +15.08% |
| May 13, 2026Q1 FY26 | −$0.45 | −$0.30 | +33.3% | — | — | — | −3.10% |
| Mar 24, 2026Q4 FY25 | −$0.41 | −$0.59 | −43.9% | — | — | — | +7.66% |
| Nov 4, 2025Q3 FY25 | −$0.40 | −$0.38 | +5.0% | — | — | — | −17.19% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$49.6M | −$42.9M | −$40.5M | −$46.0M | −$42.9M | −$52.4M | |
| Net income | −$17.9M | −$38.4M | −$137.7M | −$93.9M | $91.2M | −$253.8M | |
| Diluted EPS | −$0.24 | −$0.41 | −$1.44 | −$1.00 | −$0.42 | −$2.71 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $433.3M · Total debt $54.6M · Total assets $504.6M · Shareholders' equity $84.5M
Dividends
No dividends on record.
Ownership
Shares outstanding 134.92M · Float 129.50M · 96.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Deep Track Capital, LP | 12.16M | 9.01% | 13F | Aug 14, 2026 |
| RTW Investments, LP | 10.70M | 7.93% | 13F | Aug 14, 2026 |
| Bit Capital GmbH | 6.35M | 4.71% | 13F | Aug 12, 2026 |
| ATAI Life Sciences N.V. | 5.79M | 6.00% | 13D | Oct 29, 2025 |
| Tang Capital Management LLC | 5.00M | 3.71% | 13F | Aug 14, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Atai Beckley
Direct TRD challenger with two psychedelic candidates
- GH Research
5-MeO-DMT program in treatment-resistant depression
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Compass Pathways (ADR) | $13.79 | +0.56% | $1.85B | — | — | — | — |
| Atai Beckley | $7.29 | 0.00% | $2.70B | — | — | 602.9 | +137.0% |
| GH Research | $28.16 | +1.04% | $1.92B | — | — | — | — |
| Median | — | — | 602.9 | +137.0% |